Recently, the Department of Science and Technology of Jiangsu Province and the Department of Finance of Jiangsu Province jointly issued a document (Su Caijiao  No. 73), officially issuing the notice document of the central government to guide local science and technology development funds, and the Institute of Artificial Intelligence Biomedical Technology of Nanjing University successfully obtained the 2022 Jiangsu Provincial Science and Technology Plan Special Fund (Innovation Capacity Building Program) project approval support.
The Institute of Artificial Intelligence Biomedical Technology of Nanjing University is the world's first platform-based
scientific research institution focusing on the research and development of artificial intelligence biomedical technology,
jointly established by Nanjing University and Nanjing Jiangbei New Area in April 2019. The Institute is committed to developing
common basic technologies in the interdisciplinary fields of artificial intelligence and biomedicine, introducing and training high-level
professionals, leading the development of the field, deeply integrating with precision medicine and new drug research and development
and other industrial fields, developing new pharmaceutical biotechnology, and promoting the industrial upgrading of the biomedical
industry in the province and the country.
Relying on the three national platforms of "State Key Laboratory of Computer Software New Technology", "State Key Laboratory of
Pharmaceutical Biotechnology" and "Engineering Research Center of Protein and Peptide Drugs of the Ministry of Education" of Nanjing
University, the Institute has brought together a group of international top artificial intelligence and biomedical talents, including 1 academician
of the American Academy of Medical Sciences, 3 Changjiang scholars, 3 national outstanding young people, and 5 "National Young Talents Program"
selected. Since its establishment, the hospital has successively received the support of Jiangsu Province's entrepreneurship and entrepreneurship
team and Nanjing's top expert gathering plan.
The Institute adheres to the development strategy of attaching equal importance to basic research and industrial transformation. In terms of basic
research, under the leadership of Professor Zhang Chenyu, Dean of the School of Life Sciences, Nanjing University, the core talent team is committed
to combining the principles and technologies of artificial intelligence with biology, medicine and pharmaceutical research, and proposes original theories,
carries out original research, and develops new biomedical technologies based on artificial intelligence in the three sub-fields of artificial intelligence
structural biology, artificial intelligence precision medicine and artificial intelligence new drug research and development. In terms of industrial transformation,
since its establishment, the Institute has completed 11 scientific and technological achievement transformation projects through technology holding, technology
equity participation, technology transfer and other forms, incubated and introduced 11 biomedical companies (one each for high-tech enterprises and high-tech enterprises),
and introduced 80 million yuan of social capital. Among them, "Ai Ma Biotechnology", which was established in Jiangbei New District this year, has become a leader in the
next generation of nucleic acid drug track.
With the support of the provincial innovation capacity building plan, the Institute will continue to organically integrate basic research, technology development and achievement
transformation, build a world-class artificial intelligence biomedical technology research center, produce a number of influential original research and development results, incubate
a number of industry-leading biomedical enterprises, and strive to build a national technology innovation center and promote the development of the biomedical industry in the
province and the whole country.